Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain

NEW YORK and INDIANAPOLIS, Feb. 19, 2019 -- (Healthcare Sales & Marketing Network) -- Pfizer Inc. (NYSE: PFE) and Eli Lilly and Company (NYSE: LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab in patients with modera... Biopharmaceuticals Eli Lilly, Pfizer, tanezumab, low back pain
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news